Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review.
Osteonecrosis of the femoral head (ONFH) typically affects relatively young, active patients and frequently follows an unrelenting course resulting in considerable loss of function. In human immunodeficiency virus-infected patients, ONFH is a growing problem. Etiology, pathogenesis, and treatment of ONFH in these patients remain controversial. We analyzed retrospectively patients with ONFH in a series of 815 patients followed in our AIDS reference center. Six patients out of the 815 were affected by ONFH (0.74%). The sex ratio was 1. Two of the six patients (33.3%) had no evidence of risk factor, whereas four patients (66.6%) had risk factors. One patient had three cumulated risk factors which were corticosteroids, chemotherapy, and radiotherapy. For this patient, the onset time for ONFH was shorter (36 months). It is difficult to attribute the effect to any single class of antiretroviral agents because combination therapy is standard of care, and a change in therapies is common. All classes of antiretroviral drugs have been used: protease inhibitors (mean use duration of 15.2 months before the ONFH onset), non-nucleoside reverse transcriptase inhibitors (12 months), and nucleoside reverse transcriptase inhibitors (40.5 months). ONFH was bilateral in four cases (66.6%) and unilateral in two cases (33.3%). One patient had other osteonecrosis location (both shoulders). ONFH was classified on plain radiography stage IV in five patients and stage III in one patient. All patients received initial medical treatment. It consisted of painkillers and non-weight bearing of the hip. All were finally operated on by total hip arthroplasty (THA). The average interval between ONFH diagnosis and the first THA was 10.3 months for the six patients. A controlateral THA was performed for three patients after a mean interval of 23.3 months after ONFH diagnosis. Of the nine implanted prostheses, four were cemented, four were cementless, and one was resurfacing prosthesis.
Yombi
Jean-Cyr
JC
Department of Internal Medicine, Infectious Diseases and AIDS Reference Centre, Saint-Luc University Hospital (Université Catholique de Louvain), 10 Avenue Hippocrate, 1200, Brussels, Belgium. jean.yombi@uclouvain.be
Vandercam
Bernard
B
Wilmes
Dunja
D
Dubuc
Jean-Emile
JE
Vincent
Anne
A
Docquier
Pierre-Louis
PL
D000328:Adult; D017677:Age Distribution; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D019644:Arthroplasty, Replacement, Hip; D001530:Belgium / Q000453:epidemiology; D015897:Comorbidity; D005260:Female; D005271:Femur Head Necrosis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors
D044966:Anti-Retroviral Agents